TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04319276
Drug: Gallium maltolate (500 mg)
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Study: NCT04319276
Drug: Gallium maltolate (1,000 mg)
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Study: NCT04319276
Drug: Gallium maltolate (1,500 mg)
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Study: NCT04319276
Drug: Gallium maltolate (2,000 mg)
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Study: NCT04319276
Drug: Gallium maltolate (2,500 mg)
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Study: NCT04319276
Drug: Gallium maltolate (recommended phase 2 dose)
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maximum-tolerated dose (recommended phase 2 dose).
Study: NCT05650723
Drug: Zanubrutinib Pill
Normalized name: zanubrutinib Pill
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg once per day by mouth
Study: NCT05650723
Drug: Venetoclax Pill
Normalized name: venetoclax Pill
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
Study: NCT05650723
Drug: Obinutuzumab Injection
Normalized name: obinutuzumab Injection
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg IV given every 28 days
Study: NCT05155007
Drug: Rilematovir
Normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilematovir will be administered orally as per assigned treatment sequence.
Study: NCT05155007
Drug: Ciclosporin
Normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin will be administered orally as per assigned treatment sequence.
Study: NCT04488133
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as specified in the treatment arm.
Study: NCT04991311
Drug: Glepaglutide
Normalized name: Glepaglutide
DrugBank: Glepaglutide (DB14794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glepaglutide will be delivered in a single-use autoinjector.
Study: NCT06580782
Drug: Calcium Carbonate 500 MG
Normalized name: calcium carbonate 500 MG
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate 500mg, orally, every 4 hours.
Study: NCT06328387
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
Study: NCT06042257
Drug: Guanfacine Hydrochloride Immediate Release
Normalized name: Guanfacine Hydrochloride
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mg capsules
Study: NCT05886244
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
Study: NCT06348173
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Compare the response to mepolizumab and benralizumab before and after treatment
Study: NCT06392841
Drug: Niraparib/Abiraterone Acetate DAT
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg/ Abiraterone acetate 1000 mg orally
Study: NCT06328387
Drug: Trastuzumab Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Study: NCT06392841
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg orally
Study: NCT06392841
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg orally
Study: NCT06392841
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV
Study: NCT04523922
Drug: 40 IU Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Study: NCT05741164
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06581627
Drug: Etavopivat
Normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of Etavopivat will be administered in fasted state via oral route
Study: NCT05618002
Drug: Lemborexant
Normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
Study: NCT06090227
Drug: Metformin + Standard of Care
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
Study: NCT06417892
Drug: PD-1inhibitor
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-1 antibody was selected according to first-line drug use
Study: NCT06417892
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a small molecular anti-tumor angiogensis drug
Study: NCT06417892
Drug: albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a kind of cytotoxic chemotherapy drug
Study: NCT05611710
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)
Study: NCT06072131
Drug: Belinostat Injection
Normalized name: belinostat Injection
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
Study: NCT04700709
Drug: Sirolimus Tab.
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
Study: NCT06072131
Drug: Pralatrexate Injection
Normalized name: pralatrexate Injection
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
Study: NCT06072131
Drug: CHOP
Normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP is the comparator arm
Study: NCT06072131
Drug: COP
Normalized name: COP
DrugBank: Creatinolfosfate (DB13071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COP is given in combination with Pralatrexate
Study: NCT05398081
Drug: Cefuroxime (Zinnat®)
Normalized name: cefuroxime Oral Tablet [Zinnat]
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
Study: NCT05398081
Drug: Ceftriaxone (Rocephin®)
Normalized name: ceftriaxone Injection [Rocephin]
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
Study: NCT06581328
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV infusion
Study: NCT06581328
Drug: Vedolizumab SC
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab SC injection
Study: NCT05720754
Drug: Diquafosol tetrasodium
Normalized name: diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Study: NCT06581497
Drug: ICIs
Normalized name: bicisate
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
Study: NCT01931501
Drug: Torrent's Montelukast Sodium Chewable Tablets 5mg
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05428488
Drug: Abatacept (W12-W48)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study.
Study: NCT05785754
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab injection
Study: NCT05428488
Drug: TNF Inhibitor (W12-W48)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
Study: NCT06267118
Drug: Adrenaline
Normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
Study: NCT05506137
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
Study: NCT05428488
Drug: TNF Inhibitor (W0-W12)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
Study: NCT05035836
Drug: Zanidatamab
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05035836
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05035836
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT04750941
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
Study: NCT05347004
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809
Study: NCT06788249
Drug: Ketamine only
Normalized name: Ketamine only product
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
Study: NCT00002126
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06532799
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT06532799
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT06532799
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study: NCT06532799
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06638879
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
Study: NCT04289467
Drug: Fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label
Study: NCT03930680
Drug: Dexrazoxane
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of dexrazoxane
Study: NCT06788691
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered at 1 mg/kg once every 3 weeks
Study: NCT06037252
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06789159
Drug: VK-2019
Normalized name: penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.
Study: NCT06238531
Drug: Gusacitinib
Normalized name: Gusacitinib
DrugBank: Gusacitinib (DB15670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An orally active dual SYK/JAK kinase inhibitor
Study: NCT04796922
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
Study: NCT04796922
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab will be administered intravenously on select days as per protocol.
Study: NCT04796922
Drug: obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: obinutuzumab will be administered intravenously on select days as per protocol.
Study: NCT06239298
Drug: Donafenib Tosilate Tablets
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
Study: NCT05641935
Drug: Sulfur Hexafluoride Lipid Microspheres
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05813925
Drug: Cagrilintide
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Study: NCT05813925
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Study: NCT05813925
Drug: Placebo Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive placebo matched to semaglutide
Study: NCT05281406
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg daily or reduced dose 40 mg daily
Study: NCT05281406
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study: NCT05281406
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study: NCT05281406
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study: NCT04998851
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
Study: NCT06066359
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by (IV) vein
Study: NCT06395038
Drug: Abatacept plus Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
Study: NCT05154487
Drug: Alpelisib Pill
Normalized name: alpelisib Pill
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kinase inhibitor
Study: NCT05154487
Drug: Fulvestrant injection
Normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: estrogen receptor agonist
Study: NCT05898854
Drug: 68Ga-FAPi-46
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
Study: NCT06228053
Drug: SX-682
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose twice daily
Study: NCT06228053
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose once daily
Study: NCT05025241
Drug: NNZ-2591
Normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Study: NCT05398809
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
Study: NCT06541639
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD1 antibody
Study: NCT05754333
Drug: pudexacianinium chloride
Normalized name: CHLORIDE
DrugBank: Pudexacianinium (DB19161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT05104476
Drug: Lu AF82422
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT04584307
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab 10-20mg/kg
Study: NCT04584307
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide 2mg
Study: NCT04698330
Drug: Berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months